10-Q: TriSalus Life Sciences Q1 2026 Financial Update

TriSalus Life Sciences reports a net income of $1.539 million for Q1 2026, a significant turnaround from a net loss of $10.375 million in Q1 2025, driven by gains in fair value of financial instruments.

Summary

• TriSalus Life Sciences reported a net income of $1.539 million for the first quarter ended March 31, 2026, a substantial improvement from a net loss of $10.375 million in the same period of 2025.
• Revenue for the quarter decreased by 2.9% to $8.899 million compared to $9.167 million in Q1 2025, attributed to commercial expansion efforts.
• Cost of goods sold decreased by 17.7% to $1.230 million, leading to a stable gross profit of $7.669 million and an improved gross margin of 86.2% from 83.7% year-over-year.
• Operating expenses increased, with R&D up 6.5% to $3.216 million, Sales and Marketing up 10.1% to $7.413 million, and General and Administrative up 3.9% to $5.451 million, largely due to increased stock-based compensation.
• The company raised approximately $42.6 million in net proceeds from a public offering of common stock in February 2026.
• Cash and cash equivalents increased significantly to $56.553 million as of March 31, 2026, from $20.439 million as of December 31, 2025.
• A material weakness in internal control over financial reporting related to accounting for significant transactions remains unremediated, though remediation efforts are ongoing.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as cautiously optimistic. The significant swing to net income is positive, driven by non-cash fair value adjustments, while core revenue saw a slight dip. The successful capital raise and improved gross margins are strong positives, but the continued operating losses and unremediated material weakness in internal controls warrant careful monitoring.

Positives

• Achieved net income of $1.539 million in Q1 2026, a significant improvement from a net loss of $10.375 million in Q1 2025.
• Improved gross margin to 86.2% in Q1 2026 from 83.7% in Q1 2025, driven by lower average cost per TriNav unit.
• Successfully raised approximately $42.6 million in net proceeds from a public stock offering in February 2026.
• Significantly increased cash and cash equivalents to $56.553 million as of March 31, 2026, from $20.439 million as of December 31, 2025.
• The OrbiMed Credit Agreement was amended to reduce liquidity covenant requirements and waive prior default events.
• The company is in compliance with the Product Revenue Base requirement under the OrbiMed Credit Agreement as of March 31, 2026.

Negatives

• Revenue decreased by 2.9% to $8.899 million in Q1 2026 compared to $9.167 million in Q1 2025.
• Operating expenses increased across R&D, Sales and Marketing, and General and Administrative categories, primarily due to stock-based compensation.
• A material weakness in internal control over financial reporting related to accounting for significant transactions remains unremediated.
• The company continues to incur significant operating losses, with a loss from operations of $8.411 million in Q1 2026.

Risks

• The company's ability to raise future financing and service its indebtedness.
• Changes in applicable laws or regulations.
• The ability to retain or recruit key officers, employees, or directors.
• The success of commercializing product candidates and obtaining regulatory approvals.
• The timing and results of clinical trials and regulatory applications.
• Estimates regarding expenses, future revenue, capital requirements, and the need for additional financing.
• History of operating losses and expectations of significant expenses and continuing losses for the foreseeable future.
• The ability to execute the business strategy, including the growth potential of markets and ability to serve them.
• The ability to grow market share in existing or new markets.
• The ability to develop and maintain brand and reputation.
• The ability to partner with other companies.
• The size of the addressable markets for product candidates.
• The ability to obtain and maintain intellectual property protection and not infringe on the rights of others.
• The ability to manage growth effectively.
• The ability to maintain the listing of securities on the Nasdaq Global Market.
• The outcome of any legal proceedings.
• Unfavorable conditions in the industry, global economy, or global supply chain, including financial and credit market fluctuations, international trade relations, pandemics, political turmoil, natural catastrophes, warfare, and terrorist attacks.

Future Outlook

The company expects to continue incurring operating losses for the foreseeable future due to ongoing investments in R&D and sales and marketing. Future operations and business plans will require additional capital through equity and/or debt issuances. The company is seeking potential partners to advance the development of nelitolimod for certain indications.

Management Comments

• The company is dedicated to the research, development and commercialization of an innovative drug delivery technology platform and an immuno-oncology therapeutic, aimed at improving outcomes for patients with difficult-to-treat liver and pancreatic cancers.
• The combination of our PEDD technology with nelitolimod is focused on solving the two main barriers in the tumor microenvironment that inhibits the success of immunotherapy: high intratumoral pressure and intratumoral immunosuppression.
• We are a high growth, high margin company approaching a level of revenues that can generate sufficient cash flow to sustain our operations.
• Due to the excessive cost of capital, we do not intend to proceed to Phase II trials for that indication on our own, but we are looking for potential partners to advance that indication.
• Our PERIO-03 Phase I dose escalation in LA-PDAC is complete and we anticipate releasing a consolidated clinical update in the second half of 2026 and will begin discussions for a pharmaceutical partner for further clinical development.

Industry Context

StockSavvy.ai notes that TriSalus Life Sciences operates in the competitive oncology and medical technology space, focusing on innovative drug delivery and immuno-oncology. The company's strategy to combine its PEDD technology with nelitolimod addresses key challenges in solid tumor treatment, aligning with broader industry trends towards personalized medicine and combination therapies. The recent expansion of the TriNav product family and the pursuit of new HCPCS codes reflect efforts to enhance market penetration and reimbursement, crucial for growth in this sector.

Comparison to Industry Standards

• The company's gross margin of 86.2% is notably high, suggesting strong pricing power for its TriNav product, which is positioned as a premium technology. This compares favorably to typical gross margins in the medical device industry, which can vary widely but often fall in the 50-70% range for established products.
• The company's continued operating losses, despite revenue growth, are common for early-stage biotechnology and medical technology firms investing heavily in R&D and commercialization. Industry benchmarks show that many companies in this sector require significant external funding for extended periods before achieving profitability.
• The successful capital raise of $42.6 million through a public offering is a positive indicator in a challenging market for life sciences companies, demonstrating investor confidence in the company's technology and strategy.

Corporate Governance

Legal Proceedings

• The company is not a party to any legal proceedings and is not aware of any claims or actions pending or threatened against it.

Stakeholder Impact

• Shareholders: The successful public offering provides capital for growth, potentially leading to future value appreciation. However, the slight revenue decline and continued operating losses may temper short-term sentiment. The unremediated material weakness could also be a concern.
• Employees: Stock-based compensation continues to be a significant expense, aligning employee incentives with company performance. The company's ability to secure future funding impacts job security and growth opportunities.
• Creditors: The company has long-term debt, and its ability to service this debt is dependent on future financial performance and capital raises. Amendments to the OrbiMed Credit Agreement provide some flexibility.
• Suppliers: The company's operational stability and ability to meet payment obligations are crucial for supplier relationships.

Next Steps

• Release a consolidated clinical update for the PERIO-03 Phase I dose escalation in LA-PDAC in the second half of 2026.
• Begin discussions for a pharmaceutical partner for further clinical development of nelitolimod.
• Continue to monitor and remediate the material weakness in internal control over financial reporting.

Key Dates

Recommendation

The company has shown a significant improvement in its bottom line due to non-cash fair value adjustments, which is a positive sign. The successful capital raise and improved gross margins are also encouraging. However, the slight decline in revenue, continued operating losses, and the unremediated material weakness in internal controls suggest that the company is still in a turnaround phase and faces considerable execution risk. Therefore, a 'hold' recommendation is appropriate, pending further evidence of sustainable operational improvement and resolution of internal control issues.

Keywords

TriSalus Life Sciences, Form 10-Q, Quarterly Report, Financial Statements, Revenue, Net Income, Loss from Operations, Stock-based Compensation, Public Offering, Cash Flow, Medical Technology, Oncology, Drug Delivery, Nelitolimod, TriNav